Stockreport

Agilent Announces Update on PD-L1 CE-IVD in Urothelial Carcinoma

Agilent Technologies, Inc.  (A) 
Last agilent technologies, inc. earnings: 2/18 04:05 pm Check Earnings Report
US:NYSE Investor Relations: investor.agilent.com
PDF PD-L1 IHC 22C3 pharmDx Can Now Be Used as an Aid to Identify Urothelial Carcinoma Patients for Treatment With KEYTRUDA® (pembrolizumab) SANTA [Read more]